Lutetium-177 (known by the trade name "Pluvicto" in the United States) was FDA-approved in 2022 for the treatment of men with castrate-resistant disease who have had at least one round of chemotherapy and who have had their disease visualized on a PSMA PET scan. The indication may broaden in the coming years as more clinical trials are being conducted.

Here, medical oncologist Mark Scholz, MD, explains the treatment, the reasons for its specific indication (and how patients can use this information), and what we might expect in the near future from these recent advancements in diagnostics--that is, the PSMA PET scan--and its use with therapies, like lutetium-177.

0:07 Lutetium-177 was FDA approved in 2022. Can you tell us more about this treatment? Who is it for and how does it work?

1:59 Will doctors automatically recommend lutetium-177 when is becomes appropriate, or should patients be prepared to ask their doctors about it?

3:11 Since patients need to have chemotherapy before lutetium-177, are there any requirements for the chemotherapy protocol or would a person become eligible for lutetium-177 after a single administration of chemotherapy?

4:18 Is it possible to get lutetium-177 if a PSMA PET scan has not shown any metastatic activity?

5:24 What options does a man have if the PSMA PET scan is negative, but there are still metastatic lesions seen by other scans or tests?

6:19 What are the side effects of lutetium-177?

6:54 What do you expect from PSA after lutetium-177?

7:54 What is the process like for a patient who is going to be receiving lutetium-177? Who administers it?

8:34 What is the success rate of lutetium-177?

8:51 Based on the history of advances in prostate cancer, what do you think we can expect going forward?

10:33 Which types of metastatic cases do you think are most appropriate for lutetium-177?



Don’t know your stage? Take the quiz: Visit [ Ссылка ]

To learn more about prostate cancer visit [ Ссылка ]

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: [ Ссылка ]

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #MarkScholzMD #PCRI

свернуть